



**Anthony „Tony“ W. Fox, B.Sc | FFPM | RFCP | M.D. (Lond)  
| DipPharmMedRCP | CBiol | FIBiol**

**Managing Director, QPPV**

Anthony “Tony” W. Fox is a pharmaceutical physician with more than 25 years of experience in the industry. His previous industrial positions have been at Procter and Gamble, Glaxo Inc. (Imitrex (R), Ultiva(R), Amerge(R)), and with small companies. Formerly, Tony Fox was President of the entire EBD Group, and now continues as President of EBD Consulting Inc., (Carlsbad, CA, and Munich, Germany). Among his current professional affiliations are the American College of Clinical Pharmacology, the American Society of Pharmacology and Experimental Therapeutics, and the Society of Apothecaries of London. He is a fellow of the Institute of Biology and the Royal College of Physicians, as well as of the latter’s Faculty of Pharmaceutical Medicine. His numerous publications span industrial, pharmacological, regulatory, and experimental medicine areas.

From 1994 to 1997, Tony Fox was Vice-President for Drug Development and Regulatory Affairs at Cypros Pharmaceuticals in Carlsbad, California, where he led two drugs from IND to Phase III. Prior positions include Director of Cardiovascular and Anaesthesia clinical research at Glaxo, where he led the US sumatriptan group and chaired the international remifentanil project (1990-1994). Group Leader with Procter and Gamble (phase I and II clinical trials and medical affairs). Tony Fox obtained three degrees from the University of London: BSc major in pharmacology (first class honors, 1977), his medical degree (1980) and a doctorate in pharmacology (1988). He is a Fellow of the Faculty and holds the Diploma in Pharmaceutical Medicine (Royal Colleges of Physicians, UK). Tony Fox co-edited “Treating the Headache Patient” with Roger Cady, and was on the editorial team of the major textbook “Practice and Principles of Pharmaceutical Medicine” which is going into its third edition.